ArticleEcancermedicalscience2025
Successful treatment of metastatic dermatofibrosarcoma protuberans of the breast to the lungs with imatinib mesylate: a case report.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dermatofibrosarcoma Protuberans of the Breast: A Rare Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatofibrosarcoma protuberans (DFSPs) is a low-grade mesenchymal tumour of dermal origin. Although lung metastasis is common, primary breast involvement is a very rare occurrence. The head and neck region, trunk and extremities are the common primary sites even though any site of the body may be potentially involved. Complete surgical resection with negative margins is the standard of care for nonmetastatic cases of DFSP. To the best of our knowledge, there have been no previous reports of metastatic DFSP of the breast to the lungs among male patients in sub-Saharan Africa. This case report presents data on a 32-year-old male with metastatic DFSP of the left breast to the lungs who was successfully treated with 800 mg daily imatinib mesylate therapy and achieved a complete radiological and clinical response after 1 year of palliative therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.